Dcf Advisers, LLC Altimmune, Inc. Call Options Transaction History

Dcf Advisers, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$5.5 - $8.1 $280,500 - $413,100	-51,000 Reduced 47.22%	57,000 $349,000
Q2 2024 Aug 12, 2024	SELL	$5.91 - $10.23 $76,830 - $132,990	-13,000 Reduced 10.74%	108,000 $718,000
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $139,740 - $234,770	17,000 Added 16.35%	121,000 $1.23 Million
Q4 2023 Feb 13, 2024	BUY	$2.14 - $11.62 $10,700 - $58,099	5,000 Added 5.05%	104,000 $1.17 Million
Q3 2023 Nov 13, 2023	SELL	$2.4 - $3.45 $84,000 - $120,750	-35,000 Reduced 26.12%	99,000 $257,000
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $62,850 - $252,449	-15,000 Reduced 10.07%	134,000 $565,000
Q4 2022 Feb 13, 2023	BUY	$8.74 - $16.45 $1.11 Million - $2.08 Million	126,500 Added 562.22%	149,000 $2.45 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $240,075 - $504,225	22,500 New	22,500 $287,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $395M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Dcf Advisers, LLC with notifications on news.